Af­ter putting aside a bit­ter le­gal feud, Al­ny­lam and Dicer­na chiefs make nice with an RNAi col­lab­o­ra­tion

John Maraganore and Dou­glas Fam­brough used to be at each oth­er’s throats as Al­ny­lam pur­sued claims that its RNAi ri­vals at Dicer­na had im­prop­er­ly pur­loined the IP it had picked up from Mer­ck in a bar­gain base­ment fire sale.

But that was all set­tled up close to 2 years ago with a set­tle­ment from Dicer­na’s Fam­brough. And now the two are mov­ing ahead in a close R&D part­ner­ship that makes them col­lab­o­ra­tors on a cou­ple of key dis­ease tar­gets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.